Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.

Lab Prepares Launch of Trisomy 21 Diagnostic Test

By Labmedica International staff writers
Posted on 23 Aug 2010
A new 650-m2 laboratory will launch the Trisomy 21 (T21) diagnostic test; the launch is planned for the latter half of the year 2011.

The lab will perform validation for Sequenom's (San Diego, CA, USA) T21 noninvasive Down syndrome test. Ian Clements, senior director of the company's investor relations said that samples are currently being collected for a clinical study. About 4,000 samples will be run at the new facility in connection with the final validation of the T21 test.

The clinical trial is being led by scientists at the Women and Infants Hospital (Providence, RI, USA), which is affiliated with Brown University (Providence, RI, USA). The test is sensitive enough to identify fetal DNA circulating in the pregnant woman's blood.

Sequenom has a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited lab, the Sequenom Center for Molecular Medicine, which runs the company's cystic fibrosis and SensiGene fetal Rhesus D genotyping tests. A test for age-related macular degeneration, to be launched in the first half of 2011, will also be run out of the Grand Rapids facility. Those tests are run on Sequenom's MassArray technology, whereas the T21 test will run on sequencing technology.

"This is basically an expansion of our lab network," remarked Mr. Clements. "The core of our sequencing expertise and knowledge is here in San Diego, hence it made sense to expand our network and build a CLIA lab here."

Sequenom has a CLIA-certified and CAP-accredited lab, the Sequenom Center for Molecular Medicine, which runs the company's cystic fibrosis and SensiGene fetal Rhesus D genotyping tests. A test for age-related macular degeneration, to be launched in the first half of 2011, will also be run out of the Grand Rapids facility.

These tests are run on Sequenom's MassArray technology, whereas the T21 test will run on sequencing technology.

Sequenom anticipates getting CLIA certification and CAP accreditation for the San Diego lab in Q4 2010, he added.

Related Links:

Sequenom
Women and Infants Hospital
Brown University



EUROIMMUN AG
PURITAN MEDICAL
Sekisui Diagnostics
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).

Preeclampsia Biomarker Detected Very Early In Pregnancy

A biomarker has been discovered that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as... Read more

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Industry News

view channel

EKF Wins Distribution Contract and Regulatory Approval for Target Regions

EKF Diagnostics Holdings (Cardiff, Wales, UK), an AIM-listed point-of-care, central laboratory and molecular diagnostics business, announced that it has signed a new distribution contract in China and that one of its OEM (original equipment manufacturer) partners has received further regulatory approval across several target... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.